Cambrex announced the completion of a $50 million expansion of its large-scale active pharmaceutical ingredient (API) manufacturing capabilities at its Charles City, Iowa facility. The startup of the new manufacturing space is the culmination of a two-year project, originally announced in 2020, to increase the capacity of Cambrex's API facility by 30%. The expansion positions Cambrex with the large and most advanced API facility in the United States and ensures the long-term capacity to support Cambrex's existing customer base and future growth supported by robust market demand.

Following the expansion, Cambrex'sCharles City facility has approximately 400 employees and an installed reactor capacity of over 25,000 gallons (approximately 100 cubic meters). With multiple large-scale manufacturing areas, the facility is able to reduce production timelines by manufacturing multiple products with complex chemical syntheses in parallel. The facility is located on a 45-acre property and produces a wide range of APIs and pharmaceutical intermediates, including highly potent molecules and controlled substances.